Source: Eur Respir Rev, 29 (155) 200051; 10.1183/16000617.0051-2020
Disease area: Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Stuart Elborn. Modulator treatment for people with cystic fibrosis: moving in the right direction. Eur Respir Rev, 29 (155) 200051; 10.1183/16000617.0051-2020

Member's Comments

No comment yet.

Related content which might interest you: Tezacaftor-ivacaftor for the treatment of cystic fibrosis: what’s next? Source: International Congress 2018 – Therapeutic breakthroughs Year in Review Year: 2018 Combination therapy in idiopathic pulmonary fibrosis: the way ahead will be hard Source: Eur Respir J 2015; 45: 1208-1210 Year: 2015 Can step be a maximal test in children with cystic fibrosis? Source: Annual Congress 2009 - Paediatric lung function, imaging and methodology in health and disease Year: 2009 Does this patient have cystic fibrosis?  Source: International Congress 2017 – GR6 Paediatric Ground Round: an interactive session Year: 2017 Clinical trials in idiopathic pulmonary fibrosis: a framework for moving forward Source: Eur Respir J 2013; 42: 1446-1448 Year: 2013 Intervention trials and ventilation distribution in mild cystic fibrosis lung disease: will it all come out in the wash? Source: Eur Respir J 2011; 37: 757-759 Year: 2011 Treatment of right heart failure on pulmonary arterial hypertension: is going left a step in the right direction? Source: Eur Respir Rev 2009; 19: 4-6 Year: 2010 Lung inflammation in cystic fibrosis: an overlooked therapeutic target? Source: Virtual Congress 2020 – Cystic fibrosis: from cradle to old age Year: 2020 The treatment burden of cystic fibrosis: a day-to-day experience with treatment as someone with cystic fibrosis Source: Breathe, 17 (1) 210013; 10.1183/20734735.0013-2021 Year: 2021 Targeting interleukin-13 in idiopathic pulmonary fibrosis: from promising path to dead end Source: Eur Respir J, 52 (6) 1802111; 10.1183/13993003.02111-2018 Year: 2018 High frequency chest wall oscillation (HFCWO) in the treatment of acute pulmonary exacerbation in adult cystic fibrosis (CF) patients Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children Year: 2013 Cystic fibrosis patients: do they profit from altitiude residence? Source: Annual Congress 2006 - Man at altitude: benefits and risks of pre-existing respiratory impairment due to various diseases Year: 2006 The therapy of idiopathic pulmonary fibrosis: what is next? Source: Eur Respir Rev, 28 (153) 190021; 10.1183/16000617.0021-2019 Year: 2019 Monitoring early lung disease in cystic fibrosis: where are we now? Source: Breathe 2014; 10: 34-47 Year: 2014 A new paradigm for the management of children with cystic fibrosis at home: experiences from a Dutch cystic fibrosis clinic Source: Virtual Congress 2021 – New technologies for the management of children with respiratory diseases Year: 2021 Evaluation of a novel chest wall motion analysis system in cystic fibrosis and healthy volunteers Source: International Congress 2015 – Lung function: exploring the boundaries of the respiratory system Year: 2015 Idiopathic pulmonary fibrosis: time for greater expectations? Source: Eur Respir J, 52 (2) 1801312; 10.1183/13993003.01312-2018 Year: 2018 Patient centred research: a model for involving cystic fibrosis (CF) patients in research planning Source: International Congress 2019 – Treatments, adherence and psychosocial aspects of cystic fibrosis Year: 2019